Category: Press Release

Explore all our news . .

Recent Posts

LS Retail and FreedomPay partner to deliver unified payments worldwide

Philadelphia, Pennsylvania, July 15, 2024 (GLOBE NEWSWIRE) — LS Retail, an Aptos Company has partnered with FreedomPay, the world’s largest independent payment gateway. This partnership enables retail and hospitality businesses that use LS Retail software to deliver simpler, faster payment experiences to their customers with minimum effort. LS Retail: Supporting

Minimum Deposit Casinos Announces Completion of Full Website Revamp

Before and After: MDC Website Redesign Comparison of the Minimum Deposit Casinos website before and after the comprehensive redesign. The updated site features streamlined navigation, enhanced functionality, a modern aesthetic, updated logo, and improved user-centric features. WATERFORD, Ireland, July 15, 2024 (GLOBE NEWSWIRE) — Minimum Deposit Casinos (MDC), a premier

Nyxoah Appoints Scott Holstine as Chief Commercial Officer

Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced

‫2024 چین گوانسیان سٹیل پلیٹ انڈسٹری اوپننگ اپ اور بین الاقوامی پریسیشن پروکیورمنٹ کانفرنس گوانگچوئر کاؤنٹی،شانڈونگ صوبے میں منعقد ہوئی

گوانسیان، چین، 4 جولائی 2024ئ/سنہوا-ایشیانیٹ/– “عالمی تجارت کے لئے شانڈونگ اچھی مصنوعات” کے موضوع کے تحت 2024 چین گوانسیان سٹیل پلیٹ انڈسٹری اوپننگ اپ اور بین الاقوامی پریسیشن پروکیورمنٹ کانفرنس 26 سے 28 جون تک گوانسیان کاؤنٹی میں منعقد ہوئی۔ اسٹیل پلیٹ کی صنعت گوانسیان کاؤنٹی کی ایک منفرد اور

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment